**Curriculum Vitae**

**Carlos A. Alemany, M.D**

**2501 N. Orange Avenue, Suite 689**

**Orlando, FL 32804**

**Tel. 407-303-2024**

**Fax 407-303-2038**

[**Carlos.Alemany.MD@Adventhealth.com**](mailto:Carlos.Alemany.MD@Adventhealth.com)

**Chalemany@me.com**

**Employment**

2009-Present Hematologist/Oncologist

Advent Health Hematology and Oncology

Advent Health Medical Group

2501 N. Orange Avenue, Suite 689

Orlando, FL 32804

407-303-2024

2004-2009 Hematologist/Oncologist,

Director of Clinical Research

Florida Institute of Research, Medicine, and Surgery Cancer Center/Cancer Centers of Florida

1111 Blackwood Avenue

Ocoee, FL 34761

407-292-3000

**Postdoctoral Training:**

2001-2004 Fellowship, Hematology and Oncology

The Cleveland Clinic Foundation

Cleveland, OH

1998-2001 Internship and Residency, Internal Medicine

The Cleveland Clinic Foundation

Cleveland, OH

**Education**:

1994-1998 M.D., Ponce School of Medicine

Ponce, Puerto Rico

1989-1993 B.S., University of Puerto Rico

Cayey, Puerto Rico

Major: Natural Sciences

**Certifications**:

American Board of Internal Medicine: Oncology

(November 2004; April 2015)

American Board of Internal Medicine: Hematology

(November 2004)

American Board of Internal Medicine (August 2001)

United States Medical Licensing Examination

Step 1 (June 1996)

Step 2 (August 1997)

Step 3 (February 2000)

**Medical License:**

Florida Medical License: # ME 90038

**Honors and Awards:**

Best Doctors in America Award (2009-2023).

Top Doctors Award/Orlando Magazine 2011-2023.

US Oncology Network Top 10 Clinical Research

Enrollment Award (2008).

Dr. Jose Cintron Villalonga Award for Excellence in

Obstetrics and Gynecology (1997-1998).

Induction to Alpha Omega Alpha Medical Society (1997)

**Professional Organizations:**

American Medical Association

American College of Physicians

American Society of Hematology

American Society of Clinical Oncology

Florida Society of Clinical Oncology

Pan-American Medical Association

**Teaching Affiliations:**

Associate Professor of lnternal Medicine, University of

Central Florida, College of Medicine.

**Leadership Positions:**

2020-2021 President, Pan-American Medical Association of Central Florida

2018-Present Protocol Review Committee, Chairman, AdventHealth Cancer Institute

2016-Present Director of Clinical Research, AdventHealth Cancer Institute

2016-2020 Principal Investigator for NRG and Alliance cooperative research groups

for AdventHealth Cancer Institute

2013-2022 Director Breast Cancer Medical oncology, AdventHealth Hematology and Oncology

2012-Present Director Clinical Genitourinary Medical Oncology, AdventHealth Hematology and Oncology

2011-2014 Principal Investigator for Florida Hospital Cancer Institute for the National Surgical Adjuvant Breast and Bowel Project (NSABP).

2010- 2011 Medical Director of Cancer Institute of Florida, West campus

2009- 2010 President, Florida Institute of Research, Medicine & Surgery

Cancer Center

2007- 2008 Vice-President, Cancer Centers of Florida.

2007- 2010 Director of Clinical Research at Cancer Centers of Florida.

2007- 2022 Member at large, Pan-American Medical Association.

2001-2003 Delegate, Hematology and Oncology Fellowship

To the House Staff Association at The Cleveland Clinic Foundation.

1997-1998 President, Alpha Omega Alpha Beta Chapter of Puerto Rico,

Ponce School of Medicine/Ponce Health Sciences Medical School.

1996-1998 President, Class of 1998 of the Ponce School of Medicine/Ponce Health

Sciences Medicine School.

1996-1997 Delegate, Ponce School of Medicine for the Association

of American Medical Colleges.

**Languages:**

Spanish (Fluent written and spoken)

English (Fluent written and spoken)

**Research Projects:**

Bcl-2 expression but not p53 or p21 is a prognostic marker

in classical Hodgkin's lymphoma: A tissue microarray

study. Sup S, Alemany C, Elson P, Polhman B, Malhi S,

Thakkar S, Steinle R, Hsi ED. Abstract presented for the

United States and Canadian Anatomic Pathology Meeting,

Vancouver, Canada, March 2004.

The prevalence of vitamin B12 deficiency in plasma cell dyscrasias: A retrospective analysis. Advisor: Dr.

Mohamed Hussein. Poster presentation at the American

Society of Hematology meeting (December 2002, poster #

652-11, publication 2368).

The use of serum Brain Natriuretic Peptide to predict

cardiotoxicity from systemic chemotherapy. 2001. Gupta

R, Alemany C, Young J, Budd GT, Bolwell B, Francis G.

"Kinetics of the Binding Characteristics of Cellulase

Proteins to Different Celluloses". Oak Ridge National

Laboratories, Oak Ridge, TN. MBRS Summer Program

1991. Adviser: Dr. Jonathan Woodward.

**Clinical Trials:**

**Principal Investigator (National level):**

Principal Investigator (USON) for study 05007,

PRELUDE trial (Preventing Relapse in Lymphoma Using

Daily Enzastaurin). Phase 3, placebo controlled clinical trial.

Principal Investigator (USON) for study 08031, Phase 1 of

NKTR-102 in solid tumors.

Principal Investigator (USON) for study 08179, Phase 1 of

MPC-6827 (tubule inhibitor)+ Temozolamide in patients

with advanced melanoma.

Principal Investigator (USON) for study 08148, Phase 3

clinical trial of RAD-001 in patients with a complete

response after R-CHOP chemotherapy for poor risk

patients with Diffuse Large B cell Lymphoma.

**Principal Investigator (Local level):**

**Lung Cancer:**

Study USON 04107, Phase 3 clinical trial comparing

Docetaxel or Pemetrexed +/- Cetuximab,

Study USON 06026, Phase 3 clinical trial comparing

Erlotinib vs Placebo for EGFR + NSCLC (adjuvant).

Study USON 06005, Phase 3 study of

Paclitaxel/Carboplatin +/-AMG706 in advanced NSCLC.

Study USON 07027, Phase 1 ofIM0-2055 +

Erlotinib + Bevacizumab in 2nd line therapy of NSCLC.

Study USON 07050, Phase 3 of Amrubicin vs. Topotecan

for relapsed Small Cell lung cancer.

Study USON 06135, Phase 2 of Sunitinib in pts with

NSCLC over the age of 70.

Study USON 08044, Phase 3 of

Pemetrexate/Carboplatin/Bevacizumab vs.

Paclitaxel/Carboplatin/Bevacizumab in patients with stage

3b and 4 non-squamous cell NSCLC.

Study USON 08094, Phase 3 of Docetaxel +/-ASA-404 in

2nd line NSCLC.

**Breast Cancer:**

Study USON 06090, Phase 3 comparing

Docetaxel/ Adriamycin/Cyclophosphamide (TAC) vs. Docetaxel/Cyclophosphamide (TC) as adjuvant therapy for

locally advanced breast cancer.

Study USON 07036, Phase 3 comparing Paclitaxel +

Sunitinib vs.Paclitaxel + bevacizumab as first line in

metastatic breast cancer.

Study USON 07030, Phase 1/ 2 of AEG-35156 + weekly

paclitaxel for metastatic breast cancer.

Study USON 06030, Phase 3 trial ofFaslodex +/­

Dasatanib in post-menopausal metastatic Her-2 amplified

breast cancer.

Study USON 07040, Randomized Phase 2 study

Gemcitabine + Carboplatin with or without BSI-201 for

first line treatment of triple negative breast cancer.

Study USON 07132, Phase 3 trial of TAC vs TC vs

TC+Bevacizumbab for adjuvant treatment of localized

breast cancer.

Study USON 08200, Phase 3 of Neratinib vs. Capecitabine/lapatinib in patients with metastatic Her 2 neu

amplified breast cancer.

Study USON 09008, Phase 3 of Gemcitabine/Carboplatin

+/- BSI 201 in triple negative metastatic breast cancer.

Study USON 08225, AL TTO Adjuvant Lapatanib and/or Trastuzumab for Her-2 amplified breast cancer pts.

Study USON 09132, RTOG led study of adjuvant whole

breast radiation+/- Trastuzumab in Her-2 Neu amplified DCIS.

OP-1250-001 Study; A Phase I/II Open-label, First-in-Human,

Multicenter, Dose Escalation and Expansion Study of OP-1250 as a

single agent for patients with relapsed metastatic breast cancer.

OP-1250-003 Study; A Phase 1b Open-Label Multicenter Study of OP-1250 in combination with the CDK4/6 inhibitor Ribociclib or with the PI3K Inhibitor Alpelisib in Adult Subjects with Advanced and /or Metastatic HR Positive, Her-2 Negative Breast Cancer.

**Gastric Cancer:**

Study USON 06063, Randomized Phase 2 of Docetaxel + Oxaliplatin with or without Cetuximab in patients with

advanced gastric cancer.

**Chronic Lymphocytic Leukemia (CLL):**

Study USON 06180, Phase 1/2 of GCS-100 in CLL

Study USON 08074, Phase 3 of Chlorambucil +/­

Ofatumumab in untreated CLL

**Chronic Myelogenous Leukemia (CML):**

Study USON 06189, Phase 3 Imatinib vs. Nilotinib for

first line therapy for CML.

**Lymphoma:**

Study USON 05007, Phase 3 of Enzastaurin vs. placebo as

maintenance therapy after a complete response to R-CHOP

for Diffuse Large B-Cell Lymphoma

Study USON 06102, Phase 2 study of Romidepsin in

relapsed peripheral T-cell lymphoma.

Study USON 06138, Phase 3 study of Rituximab +/- Galiximab

in relapsed follicular NHL.

Study USON 07152, Phase 3 of Bendamustine/Rituximab

vs. either R-CVP or R-CHOP in first line treatment for

follicular NHL.

**Myelodysplastic Syndrome (MDS):**

Study USON 07168, Non-Interventional Registry for lower

risk MDS patients.

Study USON 08061, Phase 1 oral Azacitadine for refractory MDS.

**Multiple Myeloma:**

Study USON 06108, Phase 3 comparing 3 first line

regimens using bortezomib combinations. (UPFRONT study).

**Pancreas Cancer:**

Study USON 06150, Phase 1 study of Gemcitabine + RTA-

402 in advanced pancreas cancer.

Study USON 07111, Phase 2 of Gemcitabine + /­

Amplimexon in advanced pancreas cancer.

**Prostate Cancer:**

Study USON 07068, Phase 2 of Docetaxel/Prednisone +/­

At-101 in patients with metastatic prostate cancer (first line).

Talapro-3 Study; A Phase 3, Randomized, Double-Blind, Study of

Talazoparib With Enzalutamide vs. Placebo with Enzalutamide In Men

with DDR Gene Mutated Castration Sensitive Prostate Cancer.

**Rectal Cancer:**

Study USON 05102, Phase 3 preoperative study of

standard chemoradiation +/- Cetuximab for locally

advanced rectal cancer.

**Kidney Cancer:**

Study USON 07134, Phase 2 study of Perifosine post

TKI/m TOR treatment for relapsed metastatic renal cell

carcinoma.

Study USON 08029, Phase 1 of LY573636 + Sunitinib as

first line therapy for metastatic renal cell carcinoma.

Study USON 08060, Pazopanib vs. Sunitinib in 1st line

advanced/metastatic RCC.

Study Keynote 581; Lenvatinib plus Pembrolizumab or Everolimus for

Advanced Renal Cell Carcinoma. (Clear Study)

Study JNJ-42756493; Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Study Keynote 866; A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer

Study Keynote 992; A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab in Combination with chemoradiotherapy versus Chemoradiotherapy alone in Participants with Muscle-invasive Bladder Cancer.

Study Talapro-2; A phase 3, Randomized, Double blind, Placebo-controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate cancer

Proteus Study; A Randomized, double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or locally Advanced Prostate Cancer who are candidates for radical prostatectomy

Study MK-6482-011; [A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma](https://www.clinicaltrials.gov/ct2/show/NCT04586231?term=nct04586231&draw=2&rank=1)

Study MK-6482-012; An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in combination with MK-6482 and MK-7902 (Lenvatinib) or KK-1308A in combination with levantanib, vs. pembrolizumab and Lenvatinib, as Frist line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

**Phase I Studies:**

Study USON 06174, Phase 1 of Brostacillin +

bevacizumab in refractory solid malignancies.

Study USON 07083, Phase 1 of ZI0-101 in refractory solid malignancies.

Study USON 08031, Phase 1 ofNKTR-102 in the

treatment of refractory solid malignancies.

Study USON 08008, Phase lb ofLY573636 with different chemotherapy combinations (Gemcitabine, Docetaxel, Temozolamide, and Cisplatin) for patients with advanced

solid tumors.

Study USON 05033, Phase 1 of PG-11047 in different chemotherapy combinations for advanced solid tumors or lymphoma.

Study USON 09067, Phase 1 of Myostatin mAb in

refractory solid malignancies.

Study USON 09167, Phase 1 of GSK 1120212, MEK

inhibitor, in subjects with refractory solid tumors or lymphoma.

Phase 1 Dose Escalation and Dose Expansion and Phase 2 Monotherapy

Open-label, First-in-human, Multicenter Study of OP-1250 in Adults

Subjects with Advanced and/or Metastatic Hormone Receptor (HR)-positive, Her-2 negative Breast Cancer

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer.

Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER-2 + breast cancer (HER2CLIMB-02).

**Publications:**

Alemany CA, Hussein MA. Anemia in Multiple Myeloma. ***Anemia & Quality of Life in Oncology***, March 2002 Vol. 5

No.2.

Abou-Jawde R, Choueri T, Alemany C, Mekhail T.

Overview of targeted treatments in Cancer.

***Clinical Therapeutics***, 2003 Aug; Vol. 25 (8): 2121-2137.

Choueri T, Alemany CA, Abou-Jawde R, Budd GT.

The role of Aromatase Inhibitors in the Treatment of Breast Cancer. ***Clinical Therapeutics***, 2004 Aug, Vol. 26: 1199-

1214.

Baz R, Alemany CA, Green R, Hussein M.

Prevalence of vitamin B 12 deficiency in patients

with plasma cell dyscrasias: a retrospective review.

***Cancer***. 2004 Aug 15;101(4):790-5.

Sup S, Alemany C, Elson P, Polhman B, Malhi S,

Thakkar S, Steinle R, Hsi ED. Expression ofbcl-2 in

classical Hodgkin's lymphoma: an independent predictor of

poor outcome. ***J Clin Oncol***. 2005 Jun 1; 23(16):3773-9.

Hsi ED, Sup SJ, Alemany C, Tso E, Skacel M, Elson P,

Alonso MA, Pohlman B. MAL is expressed in a subset of

Hodgkin lymphoma and identifies a population of patients

with poor prognosis. ***Am J Clin Pathol.*** 2006 May; 125(5):

776-82.

Jacobson PB, Shibata D, Siegel EM, Lee JH, Alemany CA,

Brown R, Cartwright TH, Levine RM, Smith JC, Abesada­

Terk G Jr, Malafa MP. Initial evaluation of quality

indicators for psychosocial care of adults with cancer.

***Cancer Control.*** 2009 Oct; 16 (4): 328-34.

Ettinger D, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany

C, Conkling P, Spigel D, Dudek A, Shah C, Salgia R,

Mcnally R, Renschler M, Oliver, J. Phase II Study of

Amrubicin as Second-Line Therapy in Patients with

Platinum-Refractory Small-Cell Lung Cancer. ***J Clin Oncol***.

2010, May 20; 28 (15) 2598-603. Epub 2010 Apr 12.

Gray JE, Laronga C, Siegel EM, Lee JH, Fulp WJ, Fletcher

M, Schreiber F, Brown R, Levine R, Cartwright T,

Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P,

Markham MJ, Shibata D, Malafa M, Jacobsen PB.

Degree of Variability in Performance on Breast Cancer

Quality Indicators: Findings from the Florida Initiative of

Quality Cancer Care. ***J Oncol Pract.*** 2011 Jul; 7(4): 247-

251.

Jacobsen PB, Shibata D, Siegel EM, Lee JH, Fulp WJ, Alemany C, Abesada-Terk G Jr, Brown R, Cartwright T, Faig D, Kim G, Levine R, Markham MJ, Schreiber F, Sharp P, Malafa M.

Evaluating the quality of psychosocial care in outpatient

medical oncology settings using performance indicators.

***Psychooncology***. 2011 Nov; 20(11): 1221-7.

Tanvetyanon T, Corman M, Lee JH, Fulp W, Schreiber F,

Brown R, Levine R, Cartwright T, Abesada-Terk G,

Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Bepler G,

Siegel E, Shibata D, Malafa M, Jacobsen P.

Quality of Care in Non-Small Cell Lung Cancer: Findings

from 11 Oncology Practices in Florida.

***J Oncol Pract.*** 2011 Nov; e25-e3 l.

Siegel EM, Jacobsen PB, Malafa M, Fulp W, Fletcher M,

Lee JH, Smith JC, Brown R, Levine R, Cartwright T,

Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P,

Markman MJ, Shibata D.

Evaluating the quality of colorectal cancer care in the state

of Florida: Results from the Florida Initiative for Quality

Cancer Care. ***J Oncol Pract.*** *2012 Jul; 8(4): 239-45.*

Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S,

Basche M, Ramanathan RK, Borad MJ, Tibes R, Cohn A,

Hinshaw I, Jotte R, Rosen LS, Hose U, Eldon MA, Medve

R, Schroeder K, White E, Von Hoff DD.

A multicenter, phase I, dose-escation study to assess the

safety, tolerability, and pharmacokinetics of etirinotecan

pegol in patients with refractory solid tumors.

***Clin Cancer Res.*** *2013 Jan 1;19(1): 268-78*

Siegel EM, Jacobsen PB, Lee JH, Malafa M, Fulp W,

Fletcher M, Smith JC, Brown R, Levine R, Cartwright T,

Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P,

Markman MJ, Shibata D.

Florida Initiative for Quality Cancer Care: improvements

on colorectal cancer quality of care indicators during a 3-

year interval. ***J Am Coll Surg.*** 2014 Jan; 218 (1): 16-25.el-

4. Epub 2013 Nov 23.

Alemany C. Etirinotecan pegol: development of a novel

conjugated topoisomerase I inhibitor.

***Curr Oncol Rep.*** 2014 Feb; 16(2): 367.

Tanvetyanon T, Lee JH, Fulp WJ, Schreiber F, Brown RH,

Levine RM, Cartwright TH, Abesada-Terk G Jr, Kim GP,

Alemany C, Faig D, Sharp PV, Markman MJ, Malafa M,

Jacobsen PB.

Changes in the care of non-small cell lung cancer after

audit and feedback: the Florida initiative for quality cancer

care. ***J Oncol Pract***.2014 Jul; 10(4): e247-54. Epub 2014

Apr 15.

Laronga C, Gray JE, Siegel EM, Lee JH, Fulp WJ, Fletcher

M, Schreiber F, Brown R, Levine R, Cartwright T,

Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P,

Markman MJ, Shibata D, Malafa M, Jacobsen PB.

Florida Initiative for Quality Cancer Care: improvements in

breast cancer quality indicators during a 3-year interval.

***J Am Coll Surg.*** 2014 Oct; 219(4): 638-45. Epub 2014 Jul

Abaza YM, Alemany C. Nanoparticle albumin-bound­

Paclitaxel in the treatment of metastatic urethral

adenocarcinoma: the significance of molecular profiling

and targeted therapy.

***Case Rep Urol***. 2014; 2014:489686. Epub 2014 Aug 18.

Jacobsen PB, Lee JH, Fulp W, Siegel EM, Shibata D,

Laronga C, Gray J, Tanvetyanon T, Schreiber F, Brown R,

Levine R, Cartwright T, Abesada-Terk G Jr, Kim G,

Alemany C, Faig D, Sharp P, Markman MJ, Malafa M.

Florida Initiative for Quality Cancer Care: Changes in

Psychosocial Quality of Care Indicators Over a 3-year

Interval. ***J Oncol Pract***. 2014 Oct 28. JOP.2014.001525.

Tanvetyanon T, Lee JH, Fulp WJ, Schreiber F, Brown RH,

Levine RM, Cartwright TH, Abesada-Terk G, Kim GP,

Alemany C, Faig D, Sharp PV, Markman MJ, Malafa M,

Jacobsen PB.

Use of Adjuvant Cisplatin-Based Versus Carboplatin­

Based Chemotherapy in Non-Small-Cell Lung Cancer:

Findings From the Florida Initiative for Quality Cancer

Care. ***J Oncol Pract***. 2015 May 19. JOP.2014.001750.

Pech V, Abusaada K, Alemany C.

Dipeptidyl Peptidase-4 Inhibitor May stimulate progression of

Carcinoid Tumor. ***Case Rep Endocrinol.*** 2015 Jul 28.

Jacobsen PB, Lee JH, Fulp W, Siegel EM, Shibata D, Laronga C,

Gray J, Tanvetyanon T, Shreiber F, Brown R, Levine R, Cartwright T

Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P, Markman MJ,

Malafa M. Florida Initiative for Quality Cancer Care: Changes in

Psychosocial Quality of care indicators over a 3-year interval.

***J Oncol Pract***. 2015 Jan; 11 (1)e 103-9.

Yardley DA, Hart L, Favret A, Blau S, Diab S, Richard D, Sparano J,

Beck JT, Richards P, Ward P, Ramaswamy B, Tsai M, Blackwell K,

Pluard T, Tolaney SM, Esteva FJ, Truica CI, Alemany C, Volas-Redd G,

Shtivelband M, Purkayastha D, Dalal AA, Miller M, Hortobagyi GN.

Efficacy and Safety of Ribociclib with Letrozole in US Patients enrolled

in the MONALEESA-2 Study.

***Clin Breast Cancer***. 2019 Aug; 19(4): 268-277.

Cox A, Martini A, Ghozlan H, Moroose R, Zhu X, Lee E, Khaled AS,

Barr L, Alemany C, Fanaian N, Griffith E, Sause R, Litherland SA,

Khaled AR. Chaperonin containing TCP1 as a marker for identification

of circulating tumor cells in blood.

***PLoS One***. 2022 June 24; 17(6):e0264651

Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, Méndez-Vidal MJ, Tjulandin S, Hoon Park S, Melichar B, Hutson T, Alemany C, McGregor B, Powles T, Grünwald V, Alekseev B, Rha SY, Kopyltsov E, Kapoor A, Alonso Gordoa T, Goh JC, Staehler M, Merchan JR, Xie R, Perini RF, Mody K, McKenzie J, Porta CG.

Levantinib plus pembrolizumab vs. sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR); extended follow-up from the phase 3, randomized, open-label study.

***Lancet Oncol***. 2023 Mar; 24(3): 228-238.

**Publications as a contributing investigator:**

Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators.

Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia.

***N Engl J Med.*** 2010 Jun 17; 362 (24): 2251-9.

Grunwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP,

Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, RosamiliaM, Booth J, Pirotta N, Bodrogi I; REACT Study Group.

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

***Eur J Cancer.*** 2012 Feb; 48 (3): 324-32.

Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ; RECORD-1 Trial Study Group.

Survival prediction in everolimus-treated patients with metastatic

Renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.

***Eur Urol.*** 2013 Dec; 64 (6): 994-1002.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H,

Von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M,

Tomasevic Z, Denduluri N, Separovic R, Gokmen E, Bashford A, Ruiz Borrengo M, Kim SB, Jacobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan;

ExteNET Study Group

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomized,

Double-blind, placebo-controlled, phase 3 trial.

***Lancet Oncol***. 2017 Dec; 18 (12) 1688-1700.

Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; Impower 133 Study Group.

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-cell Lung Cancer.

***N Engl J Med***. 2018 Dec 6; 379 (23) 2220-2229.

Slamon D, Neven P, Chia S, Fasching P, De Laurentiis M, Im S, Petrakova K, Bianchi G, Esteva F, Martin M, Nusch A, Sonke G, De la Cruz L, Beck T, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez K, Taran T, Jerusalem G. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer; ***N Engl J Med.*** February 2020; 382:514-524.

Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma; ***N Engl J Med.*** 2021. Apr 8;384(14):1289-1300. PMID: 33616314

Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Hart L, Campone M, Petrakova K, Winer E, Janni W, Conte P, Cameron D, Andre F, Arteaga C, Zarate J, Chakravartty A, Taran T, Le Gac F, Serrra P, O’Shaughnessy J. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer; ***N Engl J Med***. March 2022; 386: 942-950.

**CME Presentations**:

Update in Oncology 2016, Pan-American Medical Association

Annual Meeting, Sarasota, FL September 2006.

Update in Myelodysplastic Syndrome, Pan-American

Medical Association Annual Meeting, Sarasota, FL,

September 2007.

Challenging Cases in Lung Cancer, October 2007,

Sponsored by Oncology Today.

Challenging Cases in Breast Cancer, November 2007,

Sponsored by Oncology Today.

Challenging Cases in Multiple Myeloma, February 2008,

Sponsored by Oncology Today.

Challenging Cases in Lung Cancer, May 2008, Sponsored

by Oncology Today.

Challenging Cases in Lymphoma, January 2009, Sponsored

by Oncology Today.

Hematological Advances from the Annual Meeting of the

American Society of Hematology, February 2009,

Sponsored by Oncology Today.

Updates in Community Oncology 2009: Improving

therapies for prostate cancer, August 2009,

Sponsored by Oncology Today.

Targeted Oncology Care 2011.

Pan-American Medical Association Annual Scientific Meeting,

Palm Coast, FL; September 2011.

Update in therapies for prostate cancer.

Florida Hospital Cancer Institute

ASCO Update

Orlando, FL; June 2011

Challenging cases in the hematology clinic.

Florida Hospital Coagulation Conference

Orlando, FL; February 2012.

Prostate Cancer Update

Florida Hospital Cancer Institute

Best of ASCO

Orlando FL; June 2012.

Advances in Prostate Cancer

Florida Hospital Cancer Institute

Best of ASCO

Orlando, FL; June 2013.

Assessment of Risk Factors for Breast Cancer.

Pan-American Medical Association Annual Scientific Meeting.

Palm Coast, FL; September 2013

Update in Oncology: The era of targeted therapy.

Pan-American Medical Association Annual Scientific

Meeting.

Palm Coast, FL; September 2014

Updates in Oncology 2017

Pan American Medical Association Annual Scientific meeting

Palm Coast, FL; September 2, 2017

What you need to know about leukemias

Pan American Medical Association Annual Scientific Meeting

Palm Coast, FL; September 2, 2018

Genitourinary oncology update 2018

Annual Oncology Nursing Society (ONS) Meeting

Central Florida Region

October 14, 2018

Risk factors associated with an increased risk for cancer

Pan American Medical Association Annual Scientific Meeting

Palm Coast, FL; September 2019

Multi-disciplinary Breast Cancer Care

Pan-American Medical Association Annual Scientific Meeting

Palm Coast, FL; September 2021

Prostate Cancer Update

Pan-America Medical Association, Annual Scientific Meeting

Palm Coast, FL; September 2022

Advanced Prostate Cancer Therapy: a primary care update

AdventHealth Cancer Institute, Genitourinary Oncology Dept.

Alfond Inn Hotel, April 2023

Updated June 2023